Column Group IV GP, LP (Kutzkey Tim, Svennilson Peter) purchased $1.0M of EIKN (indirect holdings)

Column Group IV GP, LP purchased 89,200 indirectly-held shares of Eikon Therapeutics, Inc. (EIKN) at $11.56 ($1.03M total) on 2026-09-03. Filed jointly with Column Group IV-A, LP (10% owner), Column Group IV, LP (10% owner), Column Group Opportunity III, LP (10% owner), Column Group Opportunity III GP, LP (10% owner), TCG Opportunity III GP, LLC (10% owner), Kutzkey Tim (10% owner) and Svennilson Peter (10% owner).

Original reporting
SEC EDGAR · Column Group IV GP, LP, Column Group IV-A, LP, Column Group IV, LP, Column Group Opportunity III, LP, Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Kutzkey Tim, Svennilson Peter
Published Sep 8, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EIKN
Neutral
medium confidence
Mentioned
$EIKN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EIKNNeutralLow
01

Why it matters

The disclosed purchase adds to insider ownership but is unlikely to move the stock materially.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 7/10Novelty 3/10Timing: filing date 2026-09-08

Background

Form 4 filing discloses insider transactions for publicly listed companies.

Company-level read

Ticker impact

$EIKNNeutralMedium confidence
Context

Column Group IV GP, LP bought 89,200 shares of EIKN at $11.5588, totaling $1.03M.

Expected impact

minor upside pressure, likely <$1% move.

Evidence & confidence

Purchase size is modest relative to market cap; insider ownership is 10% but transaction is routine.

Market effects

None significant for biotech sector.

No regional impact.

Minimal.

Counterpoint

Insider purchase could be a window dressing rather than genuine confidence.

Key entities

  • Eikon Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker EIKN.

  • Column Group IV GP, LP

    Insider reporting a 10% ownership stake.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EIKNMedAI 8/10

Eikon gets FDA clearance for prostate cancer drug trial

Eikon Therapeutics (EIKN) received FDA clearance for its prostate cancer drug EIK1006, advancing to Phase 1/2 trials. The study, ARGATE-001, will assess safety and efficacy in metastatic prostate cancer patients resistant to standard therapies. Dosing is expected to start in 2027, with preliminary data by late 2027. EIK1006 targets androgen receptor pathway alterations, a common cause of treatment resistance.

$EIKNMedAI 8/10

Eikon Therapeutics Reports $86.1 Million Q3 Net Loss, $461.7 Million in Cash

Eikon Therapeutics reported a Q3 2026 net loss of $86.1M, up from $71.1M a year earlier. Cash reserves totaled $461.7M. R&D expenses rose to $71.8M. The company reported clinical progress in its oncology pipeline, including NSCLC and prostate cancer trials. EIK1001 showed a 63.1% response rate in NSCLC. Eikon plans to initiate a Phase 1/2 study for EIK1006, pending FDA clearance.

$EIKNMedAI 8/10

Eikon Therapeutics Reports Third Quarter 2026 Financial Results

Eikon Therapeutics, Inc. (EIKN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates • Presented seven posters at the 2026 European Society for Medical Oncology (ESMO) Congress highlighting progress across the oncology portfolio, including clinical data from

$EIKNMedAI 8/10

Eikon Therapeutics Eyes 2027 Melanoma Trial Update, With Key Cancer Data Expected in 2029

Eikon Therapeutics (NASDAQ:EIKN) reported progress in its melanoma trial, expecting key data in 2029. The company also discussed its PARP1 inhibitors, EIK1003 and EIK1004, showing promising early results in combination therapies. Eikon's pipeline includes a Werner helicase inhibitor and an androgen receptor antagonist, with patient enrollment expected soon for the latter. The company aims to leverage its live-cell imaging technology for drug discovery in oncology and other serious diseases.